Abstract
A novel therapy for improving selectivity in cancer chemotherapy aims to modify distribution of a cytotoxic drug by generating it selectively at tumour sites. In this approach an antibody-enzyme conjugate is allowed to localise at the tumour sites before injecting a prodrug which is converted to an active drug specifically by the targeted enzyme in the conjugate. We present here pharmacokinetic studies on the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its activated derivative, benzoic acid mustard. The glutamic acid is cleaved from the prodrug to form the active drug by carboxypeptidase G2 (CPG2), an enzyme from Pseudomonas sp., which is not found in mammalian cells. The prodrug and its parent active drug were rapidly distributed in plasma and tissues after administration of prodrug or active drug (41 mumol kg-1 intraperitoneally) to mice bearing human choriocarcinoma xenografts. Prodrug and active drug both followed a two-compartment kinetic model. Prodrug was eliminated more rapidly (t1/2 alpha = 0.12 h, t1/2 beta = 0.70 h) than active drug (t1/2 alpha = 0.37 h, t1/2 beta = 1.61 h). Conversion of the prodrug to the activated parent drug was detected within 5 min of administration to mice which had previously received a F(ab')2-anti-human chorionic gonadotrophin antibody (W14A) conjugated to the enzyme, CPG2 (1,000 U kg-1). Tumour was the only tissue that activated all the prodrug reaching the site. It contained the highest concentration of targeted enzyme conjugate capable of catalysing the reaction of prodrug to drug. Plasma and other tissues were also capable of activating the prodrug but active drug production was limited by the amount of enzyme present. The active drug measured in plasma and tissues other than tumour was attributable to residual antibody-enzyme conjugate at non-tumour sites. Low levels of conjugate in tissues and plasma militate against the advantage of tumour localised enzyme therefore necessitating removal of non-localised enzyme.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagshawe K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer. 1987 Nov;56(5):531–532. doi: 10.1038/bjc.1987.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988 Dec;58(6):700–703. doi: 10.1038/bjc.1988.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bagshawe K. D. The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer. 1989 Sep;60(3):275–281. doi: 10.1038/bjc.1989.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harwood P. J., Britton D. W., Southall P. J., Boxer G. M., Rawlins G., Rogers G. T. Mapping epitope characteristics on carcinoembryonic antigen. Br J Cancer. 1986 Jul;54(1):75–82. doi: 10.1038/bjc.1986.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson V. G., Schlom J., Paterson A. J., Bennett J., Magnani J. L., Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986 Feb;46(2):850–857. [PubMed] [Google Scholar]
- Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
- Melton R. G., Searle F., Sherwood R. F., Bagshawe K. D., Boden J. A. The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model. Br J Cancer. 1990 Mar;61(3):420–424. doi: 10.1038/bjc.1990.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pedley R. B., Boden J., Keep P. A., Harwood P. J., Green A. J., Rogers G. T. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur J Nucl Med. 1987;13(4):197–202. doi: 10.1007/BF00256491. [DOI] [PubMed] [Google Scholar]
- ROSS W. C., WARWICK G. P. Reduction of cytotoxic azo compounds by hydrazine and by the xanthine oxidase-xanthine system. Nature. 1955 Aug 13;176(4476):298–299. doi: 10.1038/176298a0. [DOI] [PubMed] [Google Scholar]
- Searle F., Bier C., Buckley R. G., Newman S., Pedley R. B., Bagshawe K. D., Melton R. G., Alwan S. M., Sherwood R. F. The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br J Cancer. 1986 Mar;53(3):377–384. doi: 10.1038/bjc.1986.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Searle F., Boden J., Lewis J. C., Bagshawe K. D. A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization. Br J Cancer. 1981 Aug;44(2):137–144. doi: 10.1038/bjc.1981.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sharma S. K., Bagshawe K. D., Burke P. J., Boden R. W., Rogers G. T. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer. 1990 May;61(5):659–662. doi: 10.1038/bjc.1990.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sherwood R. F., Melton R. G., Alwan S. M., Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985 May 2;148(3):447–453. doi: 10.1111/j.1432-1033.1985.tb08860.x. [DOI] [PubMed] [Google Scholar]
- Springer C. J., Antoniw P., Bagshawe K. D., Searle F., Bisset G. M., Jarman M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem. 1990 Feb;33(2):677–681. doi: 10.1021/jm00164a034. [DOI] [PubMed] [Google Scholar]